Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Shouse

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Hematological Oncology|April 22, 2025
Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort StudyPallawi Torka, Natalie S Grover, Timothy J Voorhees, et al.
Transplantation and Cellular Therapy|May 24, 2022
Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell LymphomaPashna N Munshi, Yue Chen, Kwang W Ahn, et al.
American Journal of Hematology|March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell LymphomaGeoffrey Shouse, Matthew Matasar, Lu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL)Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity ModelMax J Gordon, Andy Kaempf, Andrea Sitlinger, et al.
Cancer Medicine|April 21, 2023
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experienceIdoroenyi Amanam, Janny Yao, Alfredo Puing, et al.
Transplantation and Cellular Therapy|November 12, 2023
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation CyclophosphamideHany Elmariah, Salman Otoukesh, Ambuj Kumar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell TherapyKyuwan Lee, Aleksi Iukuridze, Tianhui He, et al.
Transplantation and Cellular Therapy|August 5, 2024
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant CyclophosphamideHany Elmariah, Salman Otoukesh, Ambuj Kumar, et al.
Blood Advances|February 3, 2023
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphomaGeoffrey Shouse, Andy Kaempf, Max J Gordon, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Hematological Oncology|April 22, 2025
Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort StudyPallawi Torka, Natalie S Grover, Timothy J Voorhees, et al.
Transplantation and Cellular Therapy|May 24, 2022
Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell LymphomaPashna N Munshi, Yue Chen, Kwang W Ahn, et al.
American Journal of Hematology|March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell LymphomaGeoffrey Shouse, Matthew Matasar, Lu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL)Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity ModelMax J Gordon, Andy Kaempf, Andrea Sitlinger, et al.
Cancer Medicine|April 21, 2023
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experienceIdoroenyi Amanam, Janny Yao, Alfredo Puing, et al.
Transplantation and Cellular Therapy|November 12, 2023
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation CyclophosphamideHany Elmariah, Salman Otoukesh, Ambuj Kumar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell TherapyKyuwan Lee, Aleksi Iukuridze, Tianhui He, et al.
Transplantation and Cellular Therapy|August 5, 2024
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant CyclophosphamideHany Elmariah, Salman Otoukesh, Ambuj Kumar, et al.
Blood Advances|February 3, 2023
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphomaGeoffrey Shouse, Andy Kaempf, Max J Gordon, et al.
Pageof 6